[종설] 2020년 FDA 승인 방사성 의약품

• 영문명: FDA Approved Radiopharmaceuticals in 2020
• 발행기관: 대한약학회
• 저자명: 임태형(Taehyeong Lim) 하현수(Hyunsoo Ha) 변영주(Youngjoo Byun)
• 간행물 정보: 『약학회지』제65권 제3호(2021년), 169~173쪽, 전체 5쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2021.06.30

영문 초록

Radiopharmaceuticals are radioactive isotopes and labeled compounds used to diagnose and treat diseases. The global radiopharmaceutical market is expected to grow at an average annual rate of 12.4%, reaching $14,728 million by 2023. Four of the 53 new drugs approved by the US FDA in 2020 are radiopharmaceuticals. All four radiopharmaceuticals are radioisotopelabeled diagnostics used in positron emission tomography (PET) imaging. This review describes four FDA-approved radiopharmaceuticals, including incorporated radioisotopes, target proteins, modes of action, and clinical indications.

목차

서 론(Introduction)

본론: 미국 FDA 승인 방사성 의약품

결 론(Conclusion)

키워드

radiopharmaceuticals PET imaging diagnostics